Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | C3AR1 | Q16581 | 3/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | MLNR | O43193 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770782 | 0.92 | ENPP2 (0.36) | C3AR1KDM5BENPP2TRPV1GFER | |
| SCHEMBL5775415 | 0.88 | ENPP2 (0.40) | C3AR1ENPP2GRIN2BGFER | |
| SCHEMBL5774144 | 0.85 | ENPP2 (0.42) | LMNARAB9AC3AR1KDM5BENPP2 | |
| SCHEMBL5771554 | 0.80 | GRIN2B (0.40) | KDM4ELMNAMAPTRAB9AC3AR1 | |
| SCHEMBL5771819 | 0.80 | RAB9A (0.42) | KDM4ELMNAMAPTRAB9AC3AR1 | |
| SCHEMBL5776181 | 0.79 | KDM4E (0.38) | KDM4ELMNAMAPTRAB9A | |
| SCHEMBL5775704 | 0.79 | LMNA (0.39) | KDM4ELMNAMAPTRAB9AGRIN2B | |
| Trifluoroacetic Acid SCHEMBL5777361 | 0.78 | MAPT (0.44) | KDM4ELMNAMAPT | |
| SCHEMBL5799823 | 0.78 | KMT2A (0.55) | KDM4ELMNAMAPTRAB9A | |
| Trifluoroacetic Acid SCHEMBL5773673 | 0.78 | KDM4E (0.43) | KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | MOMOSE YU | 2006-04-20 | — | — | US | disclosed |
| US-7022725-B2 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-04 | — | — | US | disclosed |
| US-20040048908-A1 | Isoxazole derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1340749-A1 | ISOXAZOLE DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-09-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084690-A1 | Isoxazole derivatives | INSR, GPR119, INSRR | KDM4E 3953/4885LMNA 2770/4885MAPT 4701/4885 |
| US-20040048908-A1 | Isoxazole derivatives | GPR119, INSR, IRS1 | KDM4E 3347/4885LMNA 2605/4885MAPT 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.